[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc (JANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 940,463
  • Shares Outstanding, K 60,832
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -113,630 K
  • EBIT $ -144 M
  • EBITDA $ -160 M
  • 60-Month Beta 2.82
  • Price/Sales 96.54
  • Price/Cash Flow N/A
  • Price/Book 1.00

Options Overview Details

View History
  • Implied Volatility 71.45% (+5.08%)
  • Historical Volatility 36.08%
  • IV Percentile 17%
  • IV Rank 10.94%
  • IV High 181.74% on 11/25/25
  • IV Low 57.90% on 01/27/26
  • Expected Move (DTE 23) 1.70 (11.05%)
  • Put/Call Vol Ratio 9.80
  • Today's Volume 378
  • Volume Avg (30-Day) 542
  • Put/Call OI Ratio 1.23
  • Today's Open Interest 14,947
  • Open Int (30-Day) 13,322
  • Expected Range 13.69 to 17.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.51
  • Number of Estimates 8
  • High Estimate $-0.36
  • Low Estimate $-0.66
  • Prior Year $-0.38
  • Growth Rate Est. (year over year) -34.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.02 +18.20%
on 03/30/26
16.59 -7.26%
on 04/20/26
+1.33 (+9.46%)
since 03/20/26
3-Month
12.12 +26.98%
on 02/05/26
16.59 -7.26%
on 04/20/26
+0.25 (+1.65%)
since 01/22/26
52-Week
12.12 +26.98%
on 02/05/26
35.34 -56.45%
on 11/26/25
-14.62 (-48.72%)
since 04/22/25

Most Recent Stories

More News
Stocks Retreat on Middle East Peace Doubts

The S&P 500 Index ($SPX ) (SPY ) today is down -0.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.24%. June E-mini S&P futures...

ALK : 40.78 (-1.62%)
MSTR : 179.36 (+9.39%)
UAL : 91.71 (-5.58%)
AVGO : 422.65 (+5.09%)
INTU : 408.68 (+0.95%)
GLXY : 26.80 (+7.41%)
$IUXX : 26,937.27 (+1.73%)
COIN : 206.24 (+5.25%)
ZNM26 : 111-090s (-0.01%)
ESM26 : 7,171.25s (+1.00%)
NCLH : 19.03 (-1.55%)
STX : 579.88 (+3.57%)
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

- JANX014 expands Janux’s PSMA tumor-activated T cell engager portfolio -JANX007 is the Company’s lead prostate cancer program and primary development priority...

JANX : 15.39 (-0.45%)
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced the nomination of a development candidate...

JANX : 15.39 (-0.45%)
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population...

JANX : 15.39 (-0.45%)
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed...

JANX : 15.39 (-0.45%)
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated...

JANX : 15.39 (-0.45%)
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to...

JANX : 15.39 (-0.45%)
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager...

JANX : 15.39 (-0.45%)
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential

These two biotech disruptors are poised for triple-digit breakout gains.

KYTX : 10.23 (+5.36%)
JANX : 15.39 (-0.45%)
$SPX : 7,137.90 (+1.05%)
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Phase 1 data demonstrates durable responses and rPFS coupled with a manageable safety profile rPFS of 7.9-8.9 months in heavily pre-treated...

JANX : 15.39 (-0.45%)

Business Summary

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

See More

Key Turning Points

3rd Resistance Point 16.07
2nd Resistance Point 15.88
1st Resistance Point 15.64
Last Price 15.39
1st Support Level 15.20
2nd Support Level 15.01
3rd Support Level 14.77

See More

52-Week High 35.34
Fibonacci 61.8% 26.47
Fibonacci 50% 23.73
Fibonacci 38.2% 20.99
Last Price 15.39
52-Week Low 12.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.